The anticancer activity
of N-benzylisoindole-1,3-dione
derivatives was evaluated against adenocarcinoma (A549-Luc). First,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide activity
assay studies of two isoindole-1,3-dione derivatives were performed
against A549 cell lines. Both compounds showed inhibitory effects
on the viability of A549 cells. Then, we explored the potential of
these compounds as active ingredients by in vivo studies. Nude mice
were given A549-luc lung cancer cells, and tumor growth was induced
with a xenograft model. Then, nude mice were divided into three groups:
the control group, compound 3 group, and compound 4 group. After application
of each compound to the mice, tumor sizes, their survival, and weight
were determined for 60 days. Furthermore, toxicological studies were
performed to examine the effects of the drugs in mice. In addition
to toxicological studies, histopathological analyses of organs taken
from mice were performed, and the results were evaluated. The obtained
results showed that both N-benzylisoindole derivatives are potential
anticancer agents.